These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27152612)

  • 1. Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study.
    Mvula H; Heinsbroek E; Chihana M; Crampin AC; Kabuluzi S; Chirwa G; Mwansambo C; Costello A; Cunliffe NA; Heyderman RS; French N; Bar-Zeev N;
    PLoS One; 2016; 11(5):e0154997. PubMed ID: 27152612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of uptake of newly introduced vaccines in Malawi - monovalent human rotavirus and pneumococcal conjugate vaccines: Evidence from the 2015-16 Malawi demographic and health survey.
    Ntenda PAM; Mwenyenkulu ET; Putthanachote N; Nkoka O; Mhone TG; Motsa MPS; Tizifa T
    J Trop Pediatr; 2019 Jun; 65(3):287-296. PubMed ID: 30085260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The composition of demand for newly launched vaccines: results from the pneumococcal and rotavirus vaccine introductions in Ethiopia and Malawi.
    Williams BA; Kidane T; Chirwa G; Tesfaye N; Prescott MR; Scotney ST; Valle M; Abebe S; Tambuli A; Malewezi B; Mohammed T; Kobayashi E; Wootton E; Wong R; Dosani R; Subramaniam H; Joseph J; Yavuz E; Apple A; Le Tallec Y; Kang'ethe A
    Health Policy Plan; 2016 Jun; 31(5):563-72. PubMed ID: 26856361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological challenges in measuring vaccine effectiveness using population cohorts in low resource settings.
    King C; Beard J; Crampin AC; Costello A; Mwansambo C; Cunliffe NA; Heyderman RS; French N; Bar-Zeev N;
    Vaccine; 2015 Sep; 33(38):4748-55. PubMed ID: 26235370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population impact and effectiveness of sequential 13-valent pneumococcal conjugate and monovalent rotavirus vaccine introduction on infant mortality: prospective birth cohort studies from Malawi.
    King C; Bar-Zeev N; Phiri T; Beard J; Mvula H; Crampin A; Heinsbroek E; Hungerford D; Lewycka S; Verani J; Whitney C; Costello A; Mwansambo C; Cunliffe N; Heyderman R; French N;
    BMJ Glob Health; 2020 Sep; 5(9):. PubMed ID: 32912855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake and timeliness of rotavirus vaccination in Norway: The first year post-introduction.
    Valcarcel Salamanca B; Hagerup-Jenssen ME; Flem E
    Vaccine; 2016 Sep; 34(39):4684-4689. PubMed ID: 27522178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of monovalent rotavirus vaccine on diarrhoea-associated post-neonatal infant mortality in rural communities in Malawi: a population-based birth cohort study.
    Bar-Zeev N; King C; Phiri T; Beard J; Mvula H; Crampin AC; Heinsbroek E; Lewycka S; Tate JE; Parashar UD; Costello A; Mwansambo C; Heyderman RS; French N; Cunliffe NA;
    Lancet Glob Health; 2018 Sep; 6(9):e1036-e1044. PubMed ID: 30103981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coverage and timeliness of vaccination and the validity of routine estimates: Insights from a vaccine registry in Kenya.
    Adetifa IMO; Karia B; Mutuku A; Bwanaali T; Makumi A; Wafula J; Chome M; Mwatsuma P; Bauni E; Hammitt LL; Mataza C; Tabu C; Kamau T; Williams TN; Scott JAG
    Vaccine; 2018 Dec; 36(52):7965-7974. PubMed ID: 30416017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between childhood immunisation coverage and proximity to health facilities in rural settings: a cross-sectional analysis of Service Provision Assessment 2013-2014 facility data and Demographic and Health Survey 2015-2016 individual data in Malawi.
    Johns NE; Hosseinpoor AR; Chisema M; Danovaro-Holliday MC; Kirkby K; Schlotheuber A; Shibeshi M; Sodha SV; Zimba B
    BMJ Open; 2022 Jul; 12(7):e061346. PubMed ID: 35879002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods and challenges in measuring the impact of national pneumococcal and rotavirus vaccine introduction on morbidity and mortality in Malawi.
    Bar-Zeev N; Kapanda L; King C; Beard J; Phiri T; Mvula H; Crampin AC; Mwansambo C; Costello A; Parashar U; Tate JE; Verani JR; Whitney CG; Heyderman RS; Cunliffe NA; French N;
    Vaccine; 2015 May; 33(23):2637-45. PubMed ID: 25917672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-appropriate versus up-to-date coverage of routine childhood vaccinations among young children in Israel.
    Stein-Zamir C; Israeli A
    Hum Vaccin Immunother; 2017 Sep; 13(9):2102-2110. PubMed ID: 28696824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An assessment of PCV13 vaccine coverage using a repeated cross-sectional household survey in Malawi.
    Bondo A; Nambiar B; Lufesi N; Deula R; King C; Masache G; Makwenda C; Costello A; Rhoda D; McCollum ED; Colbourn T
    Gates Open Res; 2018 Aug; 2():37. PubMed ID: 30569035
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timeliness and completeness of vaccination and risk factors for low and late vaccine uptake in young children living in rural southern Tanzania.
    Le Polain de Waroux O; Schellenberg JR; Manzi F; Mrisho M; Shirima K; Mshinda H; Alonso P; Tanner M; Schellenberg DM
    Int Health; 2013 Jun; 5(2):139-47. PubMed ID: 24030114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
    Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
    Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany.
    van der Linden M; Falkenhorst G; Perniciaro S; Fitzner C; Imöhl M
    PLoS One; 2016; 11(8):e0161257. PubMed ID: 27526117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting.
    Doll MK; Buckeridge DL; Morrison KT; Gagneur A; Tapiero B; Charest H; Quach C
    Vaccine; 2015 Dec; 33(51):7307-7314. PubMed ID: 26546262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with 3-dose paediatric rotavirus vaccine (RotaTeq®): impact on the timeliness of uptake of the primary course of DTPa vaccine.
    Wendy B
    Vaccine; 2012 Jul; 30(35):5293-7. PubMed ID: 22575163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.